Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.
Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.
Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.
Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.
Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.
Dr. David Spigel gives his view on more widespread availability of new mutation tests, provides his perspective on the likelihood that molecular...
Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nintedanib (BIBF-1120...
Dr. Heather Wakelee, from Stanford University, describes which molecular markers she seeks for NSCLC patients. [powerpress]
Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive...
Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based...
December 17, 2017 at 3:25 pm #1293645 jkkwok1 I was diagnosed with stage 3b NSCLC (T1N3M0) in March 2017. T1N3M0 I have gone through 2 rounds (12 days...
March 17, 2018 at 8:12 am #1294101 masalovai I have stage 4 NSCLC adenocarcinoma with bone metastasis. I started carboplatin Alimta Avastin chemo...
Hi. I have NSCLC adenocarcinoma, diagnosed 2013 with 3.5cm tumour upper right lung. I am female aged 60’s, never smoker, previously well and fit...
March 22, 2018 at 11:53 pm #1294125 mazza55 Hi. I have NSCLC adenocarcinoma, diagnosed 2013 with 3.5cm tumour upper right lung. I am female aged 60’s...
If you'd like to stay informed about the latest GRACE developments, you can subscribe to our free GRACE Notes newsletter. Just fill in the form here...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.